Rekomendatsii po lecheniyu bronkhial'noy astmy s uchetom dostizheniya kontrolya zabolevaniya


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In modern society, bronchial asthma (BA) is one of the most common diseases. According to world statistics, there are about 300 million patients with BA. Thus, disease occurs more than in 5 % of cases among the adult population; children are ill more often - up to 10 %. There are countries with prevalence of BA among the population 15 % (New Zealand, Ireland). There is also a lot of credible evidence of increase of incidence of BA in many countries. Despite the absolute progress in diagnosis and treatment of BA in the past two decades, the issues of diagnosis, treatment and disease control remain relevant. The main objective of treatment of BA is achievement of disease control, which implies the absence of symptoms or their minimal severity, no limitations in daily activities and no need (or minimal) for emergency medications, and extremely low frequency of exacerbations. Control of BA, which consists of correction of manifestations of the disease, is reached by an adequate and rational drug therapy.

Full Text

Restricted Access

About the authors

N. P Knyazheskaya

References

  1. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy 2004;59:469-78.
  2. Бронхиальная астма. Глобальная стратегия: совместный доклад Национального института Сердце, Легкие, Кровь и Всемирной организации здравоохранения // Пульмонология 1996.
  3. Global Initiative for Asthma. Workshop Report. 2006. http://www.ginasthma.com/download. asp?intId=217
  4. www.ginasthma.com (last accessed November 2009).
  5. Promotion of eosinophil survival by human bronchial epithelial cells and its modulation by steroids. Am J Respir Cell Molec Biol 1991; 4:525-31.
  6. Borson D, Gruenert D. Glucocorticoids induce neutral endopeptidase in transformed human tracheal epithelial cells. Am J Physiol 1991;260:83-9.
  7. Jeffery P, Godfrey W, Adelroth E, et al. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. Am Rev Respir Dis 1992;145:890-99.
  8. Johnson M. Pharmacodynamics and pharmaco-kinetics of inhaled glucocorticoids. J Allergy Clin Immunol 1996;97:169-76.
  9. Mak J, Nishikawa M, Barnes P. Glucocorticoids increase @2-adrenergic receptor transcription in human lung. Am J Physiol 1995;268:41-6.
  10. Mak J, Nishikawa M, Shirasaki H, et al. Protective effects of a glucocorticoid on downregulation of pulmonary@2-adrenergic receptors in vivo. J Clin Invest 1995;96:99-106.
  11. Цой АН. Ингаляционные глюкокортикоиды: эффективность и безопасность// РМЖ 2001. № 9. С. 182-85.
  12. Barnes PJ. Clinical outcome of adding long-acting β-agonists to inhaled corticosteroids. Respir Med 2001;95(B):12-6.
  13. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting /32-agonists and corticosteroids. Eur Respir J 2002;19:182-91.
  14. Mak JCW, Nishikawa M, Shirasaki H, et al. Protective effects of a glucocorticoid on down-regulation of pulmonary (32-adrenergic receptors in vivo. J Clin Invest 1995;96:99-106.
  15. http://www.fda.gov/
  16. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129-36.
  17. Kuna P, Peters MJ, Buhl R. Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone. Abstract presented at the ERS Congress 2006.
  18. Rabe K, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised, controlled, double-blind study. Lancet 2006;368:744-53.
  19. Vogelmeier C, D'Urzo A, Pauwels R, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005;26(5):819-28.
  20. Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Current Medical Research Opinion 2004;20(9):1403-18.
  21. Rabe K F, Pizzichini E, Sallberg B, et al. Budesonide/Formoterol in a Single Inhaler for Maintenance and Relief in Mild-to-Moderate Asthma: A Randomized, Double-Blind Trial, Chest, Feb 2006;129:246.
  22. Holgate S, Dahlen S-E. SRS-A to Leukotrienеs, 1997.
  23. O'Byrne PM. Leukotrienes in the pathogenesis of asthma. Chest 1997;111:27-34. Несмотря на проводимое лечение препаратами различных групп, для многих пациентов с тяжелой астмой невозможно достичь ее контролируемого течения. Этот факт требует поиска новых эффективных путей в лечении этого заболевания.
  24. Drazen JM. Pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors in the management of asthma. Pharmacotherapy 1997;17(1 Pt 2):22-30.
  25. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study. JAMA 1998;279(15):1181.
  26. Lepeleire I, Reiss TF, Rochette F, et al. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther 1997;61:83-92.
  27. O'Byrne PM. Exercise-induced bronchoconstriction: elucidating the roles of leukotrienes and prostoglandins. Pharmacotherapy 1997; 17(1 Pt 2):31-8.
  28. Okudaira H. Challenge Studies of a leukotriene receptor antagonist. Chest 1997;111:46-51.
  29. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60:302-8.
  30. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16.
  31. Zeldin R, Massanari M, Maykut R, et al. Omalizumab reduced the need for steroid bursts in asthmatics concomitantly using leukotriene receptor antagonists (LTRAs). J Allergy Clin Immunol 2006;117(2):280,1080(abstr.).
  32. Cruz AA, Lima F, Sarinho E, et al. Safety of antiimmunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy 2007;37:197-207.
  33. Bel EH. Severe asthma Breath 2006;3(2): 129-39.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies